Product Description
Mechanisms of Action: C3 Inhibitor
Novel Mechanism: No
Modality: Nucleic Acid
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Rigerna Therapeutics, Beijingï¼ Rigerna Therapeutics, Suzhouï¼ Rigerna OA Therapeutics Pty Ltd
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for RG-002C0106](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
RG002C0106-001 | P1 |
Not yet recruiting |
Healthy Volunteers |
2025-10-20 |